Mitomycin c intravesical therapy in noninvasive bladder cancer after failure on thiotepa

Brian F. Issell, George R. Prout, Mark S Soloway, Kenneth B. Cummings, George Brannen, Ralph Veenema, Malachi Flanagan, Norman L. Block, Jack L. Summers, Elizabeth A. Levin, M. Dianne Defuria

Research output: Contribution to journalArticle

27 Scopus citations

Abstract

Mitomycin C 40 mg in 40 ml water was administered intravesically every week for 8 consecutive weeks to 60 patients with superficial bladder cancer. All patients had failed treatment with intravesical thiotepa and had evaluable disease. An objective response of 50% or greater reduction in measured tumor mucosal involvement was obtained in 68% of patients. Forty-two percent of the patients achieved a complete response, and this included 50% of patients with Grade III disease and 70% of patients with a T1 tumor. Median response duration in complete responders was 12.2 months with a range of 3.5 to 24.3+ months. Fifty-five percent of patients are still responding. Therapy was generally well tolerated, and in contrast to thiotepa, myelosuppression was not the dose-limiting effect. One third of all patients experienced symptoms of local irritation, and skin reactions were seen in 12% of patients.

Original languageEnglish (US)
Pages (from-to)1025-1028
Number of pages4
JournalCancer
Volume53
Issue number5
DOIs
StatePublished - Mar 1 1984

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Mitomycin c intravesical therapy in noninvasive bladder cancer after failure on thiotepa'. Together they form a unique fingerprint.

  • Cite this

    Issell, B. F., Prout, G. R., Soloway, M. S., Cummings, K. B., Brannen, G., Veenema, R., Flanagan, M., Block, N. L., Summers, J. L., Levin, E. A., & Dianne Defuria, M. (1984). Mitomycin c intravesical therapy in noninvasive bladder cancer after failure on thiotepa. Cancer, 53(5), 1025-1028. https://doi.org/10.1002/1097-0142(19840301)53:5<1025::AID-CNCR2820530502>3.0.CO;2-D